← back to search

Maria Luiza Caramori

University of Minnesota · US
Area of research
Nephrology · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Chronic Kidney Disease and Diabetes, Diabetes Treatment and Management, Renal Diseases and Glomerulopathies, and Blood Pressure and Hypertension Studies.
h-index
31
citations
6,104
works
80
NIH funding
primary concept
Medicine
email

Recent publications

Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update
Annals of Internal Medicine 2023cited by 230position: middledoi
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of <scp>HbA1c</scp> at baseline, <scp>HbA1c</scp> variability, diabetes duration and insulin use at baseline
Diabetes Obesity and Metabolism 2023cited by 14position: middledoi
Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence
Kidney International 2022cited by 265position: middledoi
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use
Diabetes Obesity and Metabolism 2022cited by 40position: middledoi
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
New England Journal of Medicine 2020cited by 355position: middledoi
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
Kidney International 2020cited by 279position: middledoi
Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline
Annals of Internal Medicine 2020cited by 164position: middledoi
Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen
Journal of the American Society of Nephrology 2019cited by 213position: middledoi
Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol—Rationale, Design, and Baseline Data
Diabetes Care 2019cited by 48position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Peter Rossing · University of Glasgow6 papers (2020–2023)Nikhil Tandon · Indian Institute of Public Health Gandhinagar4 papers (2020–2023)Tami Sadusky · Seattle University4 papers (2020–2023)David J. Tunnicliffe · University of Sydney4 papers (2020–2023)Katy G. Wilkens · VA Northwest Network4 papers (2020–2023)Hiddo J.L. Heerspink · Kidney Associates4 papers (2020–2023)Ian H. de Boer · University of Washington4 papers (2020–2023)Sophia Zoungas · Monash University4 papers (2020–2023)Christoph Wanner · Smart Material (Germany)4 papers (2020–2023)Marcello Tonelli · Institute of Public Health Zadar4 papers (2020–2023)Erin D. Michos · Vanderbilt University Medical Center4 papers (2020–2023)Jonathan C. Craig · Murdoch Children's Research Institute4 papers (2020–2023)Adrian Liew · International Society of Nephrology4 papers (2020–2023)Katherine R. Tuttle · University of Washington School of Medicine4 papers (2020–2023)Michael Cheung · Royal Children's Hospital4 papers (2020–2023)Amy Earley · Lake Superior State University4 papers (2020–2023)Clint Hurst · University of Houston4 papers (2020–2023)Kamlesh Khunti · University Hospitals of North Midlands NHS Trust4 papers (2020–2023)Sankar D. Navaneethan · Michael E. DeBakey VA Medical Center4 papers (2020–2023)Juliana C.N. Chan · SAIC-GM (China)4 papers (2020–2023)